We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
TVGN

Price
1.20
Stock movement up
+- (%)
Company name
Tevogen Bio Holdings Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
236.05M
Ent verdi
-
Pris/omsetning
-
Pris/bok
-
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
37.93%
3 års avkastning
-
5 års avkastning
-
10 års avkastning
-
Sist oppdatert: 2025-08-27

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UTBYTTE

TVGN betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning-
Pris til bok-
EV i forhold til salg-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

ØKONOMI

iO Charts is a Seeking Alpha partner

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning1.22
Daglig høy1.24
Daglig lav1.19
Daglig volum598K
Tidenes høyeste10.00
1 år analytikerestimat10.00
Beta-0.75
EPS (TTM)-
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon-

Nedsidepotensial

Loading...
Nedsidepotensial-data
TVGNS&P500
Nåværende prisfall fra toppnotering-88.00%-3.04%
Høyeste prisfall-97.41%-56.47%
Dato for høyeste fall9 Oct 20249 Mar 2009
Gj.snittlig fall fra topp-83.22%-11.04%
Gj.snittlig tid til ny topp85 days12 days
Maks tid til ny topp337 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

SELSKAPSOPPLYSNINGER
TVGN (Tevogen Bio Holdings Inc) company logo
Markedsverdi
236.05M
Markedsverdi kategori
Small-cap
Beskrivelse
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Ansatte
18
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FORSTÅ VIRKSOMHETEN
Loading...